Kume M, Suzuki R, Yatabe Y, Kagami Y, Miura I, Miura A B, Morishima Y, Nakamura S, Seto M
Laboratory of Chemotherapy, Aichi Cancer Center Research Institute.
Jpn J Cancer Res. 1997 Nov;88(11):1087-93. doi: 10.1111/j.1349-7006.1997.tb00333.x.
De novo CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBL) has recently been identified as constituting a homogeneous subgroup with distinct clinicopathologic and genotypic characteristics, but its origin remains to be elucidated. Previous studies by sequence analysis of the variable region of the immunoglobulin heavy chain (VH) have shown that CD5+ B-cell malignancies such as mantle cell lymphoma (MCL) and B-cell chronic lymphocytic leukemia (B-CLL) cells represent pre-germinal center (pre-GC) stage B cells in contrast with the post-GC stage of most DLBLs, which show somatic hypermutations in VH genes. In the present study, we investigated the VH sequence of de novo CD5+ DLBL to clarify whether CD5+ DLBL represents the pre-GC stage, as do other CD5+ B-cell malignancies, or the post-GC stage, as is typical of DLBL. All eight cases (four CD5+ DLBL and four CD5-negative (CD5-) DLBL) examined by us showed somatic hypermutations in the VH segment and two of the CD5- DLBL cases showed intra-clonal diversity, suggesting that CD5+ DLBLs were derived from the same maturation stage as CD5- DLBL, but were distinct from the other indolent CD5+ B-cell lymphomas of B-CLL and MCL. These data suggest that de novo CD5+ DLBLs do not merely lie within a continuous spectrum with B-CLL and MCL, but represent a biologically distinct variant within the diagnostic framework of diffuse large B-cell lymphoma.
新发CD5阳性(CD5+)弥漫性大B细胞淋巴瘤(DLBL)最近被确定为一个具有独特临床病理和基因特征的同质亚组,但其起源仍有待阐明。先前通过免疫球蛋白重链(VH)可变区序列分析的研究表明,与大多数DLBL的生发中心后阶段(VH基因存在体细胞超突变)不同,CD5+ B细胞恶性肿瘤如套细胞淋巴瘤(MCL)和B细胞慢性淋巴细胞白血病(B-CLL)细胞代表生发中心前(pre-GC)阶段的B细胞。在本研究中,我们调查了新发CD5+ DLBL的VH序列,以阐明CD5+ DLBL是像其他CD5+ B细胞恶性肿瘤一样代表生发中心前阶段,还是像DLBL典型情况那样代表生发中心后阶段。我们检测的所有8例病例(4例CD5+ DLBL和4例CD5阴性(CD5-)DLBL)的VH片段均显示体细胞超突变,其中2例CD5- DLBL病例显示克隆内多样性,这表明CD5+ DLBL与CD5- DLBL源自相同的成熟阶段,但与B-CLL和MCL等其他惰性CD5+ B细胞淋巴瘤不同。这些数据表明,新发CD5+ DLBL并非仅仅处于与B-CLL和MCL的连续谱系中,而是在弥漫性大B细胞淋巴瘤的诊断框架内代表一种生物学上独特的变体。